Pharmacology/Pharmaceutical Industry | Page 113 of 172 | Links Medicus Content Curation & Alerts in Medicine

Kudos to @MartinLandray and team, including all patients, practitioners, administrators, funders & researchers. Amazing study. This is the new standard about how to move quickly, thoughtfully and effectively in research. Now @medrxivpreprint. Pls comment. https://t.co/0MBY13Uxvc pic.twitter.com/fFx3166nCJ

— Harlan Krumholz (@hmkyale) June 22, 2020

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

23 Jun, 2020 | 08:19h | UTC

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges – Journal of the American Heart Association

Drug Dosing in the Critically ill Obese Patient—A Focus on Sedation, Analgesia, and Delirium

23 Jun, 2020 | 08:15h | UTC

Drug dosing in the critically ill obese patient—a focus on sedation, analgesia, and delirium – Critical Care

Related Commentary on Twitter

#CritCare #OpenAccess https://t.co/AXi5FOLBAC #Drug_dosing recommendations are often based on patients with normal body habitus. What about #pharmacokinetics of critically ill #obese patients?#FOAMed #FOAMcc #BMC #ICU @jlvincen @ISICEM #obesity #pain #agitation #delirium pic.twitter.com/QMWEmeyDpX

— Critical Care (@Crit_Care) June 23, 2020

NIH Halts Clinical Trial of Hydroxychloroquine

21 Jun, 2020 | 23:44h | UTC

NIH halts clinical trial of hydroxychloroquine – NIH News Releases

Covid-19: Another Study Shows ACEI/ARB Use is Not Associated with Increased Mortality Risk

21 Jun, 2020 | 23:40h | UTC

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality – JAMA

Editorial: Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19 – JAMA

Antidepressants and Movement Disorders: A Postmarketing Study in the World Pharmacovigilance Database

21 Jun, 2020 | 23:23h | UTC

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database – BMC Psychiatry

Association of Azithromycin Use with Cardiovascular Mortality

21 Jun, 2020 | 23:21h | UTC

Association of Azithromycin Use With Cardiovascular Mortality – JAMA Network Open

Commentary: Azithromycin tied to higher risk of death – CIDRAP

Randomized Trial: Tranexamic Acid Does Not Reduce Death from Gastrointestinal Bleeding

19 Jun, 2020 | 09:32h | UTC

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial – The Lancet

Invited Commentary: Tranexamic acid for severe gastrointestinal bleeding – The Lancet

ACP Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination with Azithromycin for the Prophylaxis or Treatment of COVID-19?

18 Jun, 2020 | 08:59h | UTC

Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians – Annals of Internal Medicine

WHO To Include Dexamethasone in Updated COVID-19 Care Guidelines; Drops Hydroxychloroquine from Massive Solidarity Trial

18 Jun, 2020 | 09:02h | UTC

World Health Organization to Include Dexamethasone In Updated COVID-19 Care Guidelines; Drops Hydroxychloroquine From Massive Solidarity Trial – Health Policy Watch

Study Commentary: Fluconazole During Pregnancy – Is It Safe?

18 Jun, 2020 | 08:46h | UTC

Fluconazole During Pregnancy – Is It Safe? – Journal Feed

Original Study: Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study – The BMJ

Study Commentary: Haloperidol for Headache – THE HA Study RCT

18 Jun, 2020 | 08:44h | UTC

Haloperidol for Headache – THE HA Study RCT – Journal Feed

Original Study: Treatment of Headache in the Emergency Department: Haloperidol in the Acute Setting (THE-HA Study): A Randomized Clinical Trial – The Journal of Emergency Medicine (link to abstract – $ for full-text)

Randomized Trial: Dexamethasone Reduces Death by Up to One Third in Patients with Severe COVID-19

17 Jun, 2020 | 02:49h | UTC

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

Commentaries: Coronavirus breakthrough: dexamethasone is first drug shown to save lives – Nature AND WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients – World Health Organization AND Major study finds common steroid reduces deaths among patients with severe Covid-19 – STAT AND Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19 – University of Oxford AND Coronavirus: Dexamethasone proves first life-saving drug – BBC

Related Commentary on Twitter

Dexamethasone reduced deaths by 1/3rd in ventilated patients (rate ratio 0.65 [95% CI 0.48 to 0.88]; p=0.0003) and by 1/5th in patients receiving oxygen only (0.80 [0.67 to 0.96]; p=0.0021). No benefit in patients not requiring respiratory support (1.22 [0.86 to 1.75; p=0.14).

— Peter Horby @peterhorby.bsky.social (@PeterHorby) June 16, 2020

Cohort Study: Ibuprofen Use Not Associated with Worse Outcomes in Covid-19 Patients

17 Jun, 2020 | 02:41h | UTC

Ibuprofen use and clinical outcomes in COVID-19 patients – Clinical Microbiology and Infection

Related Commentary on Twitter

A new cohort @CMIJournal :
403 COVID-19 patients, Ibuprofen use was NOT associated with worse clinical outcomes, compared to paracetamol or no antipyretic
Ibuprofen use and clinical outcomes in #COVID19 patients.
⛔Median age : 45, younghttps://t.co/Y4WL2UsIDU

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) June 12, 2020